December 2024 in “African Journal of Biomedical Research” Combining dexmedetomidine and ketamine provides better sedation and pain relief than dexmedetomidine alone.
16 citations
,
August 2004 in “Tetrahedron” Scientists made all eight versions of a compound called cyoctol, but found it's not an anti-androgen and it fully breaks down in the skin.
5 citations
,
December 2015 in “PubMed” Some gonadal hormone drugs can block filovirus entry into cells.
January 2023 in “IntechOpen eBooks” The document concludes that specific methods for making diazine-based drugs can lead to high yields and are important for creating effective treatments for various diseases.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
9 citations
,
June 2014 in “Nutrition and Cancer” Eclipta alba extract may work as an anticancer agent and help reverse drug resistance.
1 citations
,
April 2025 in “Tropical Journal of Natural Product Research” Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.
January 2026 in “Open MIND” Targeting the PIEZO1 and MLCK axis may offer a new treatment for hair loss.
64 citations
,
March 2008 in “Neuropsychopharmacology” 99 citations
,
August 1998 in “Pain” Blocking GABA(A) receptors increases neuron sensitivity, showing GABA and glycine have different roles in pain.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
100 citations
,
October 2006 in “Rapid Communications in Mass Spectrometry” A quick method effectively detects banned substances in urine.
September 2025 in “Journal of the American Academy of Dermatology” Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
August 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.
3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
April 2011 in “ChemInform” A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
1 citations
,
April 2024 in “Journal of Dermatological Science”
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The N-K GM Series offers highly selective, eco-friendly medicines targeting harmful microbes, free for personal use.
25 citations
,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
1 citations
,
May 2024 in “Pediatric Blood & Cancer” Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.
9 citations
,
August 2023 in “Molecules” Two peptides, RMYYY and VMYMI, may be effective anti-inflammatory drugs.
60 citations
,
January 2004 in “The journal of investigative dermatology/Journal of investigative dermatology” Applying a specific inhibitor lightens skin and hair color.
The document corrects a mistake by stating that pimecrolimus, not tacrolimus, is the drug that concentrates in the skin.
The research found how certain drugs and polymers form stable complexes, which could help develop new pharmaceutical forms.
18 citations
,
December 2016 in “European journal of pharmacology” A new compound slows cancer cell growth and causes cell death by blocking cell cycle progression and increasing cell-damaging molecules.
November 2018 in “The Journal of Allergy and Clinical Immunology: In Practice” Using old drugs for new uses can help treat rare immune deficiencies.
December 2022 in “International Journal of Molecular Sciences” Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.